Sihuan Pharmaceutical (HKG: 0460) announced that two self‑developed, self‑manufactured aesthetics products from its subsidiary Meiyan Space — the Polycaprolactone Microsphere Facial Filler for Injection (PCL) and the Hyaluronic Acid Sodium Composite Solution for Injection (FL), a novel “skin booster” — have successively been approved for market launch in the Hong Kong Special Administrative Region of China, extending the company’s aesthetics franchise beyond the mainland.
Regulatory Milestones
| Item | Detail |
|---|---|
| Company | Sihuan Pharmaceutical (HKG: 0460), via subsidiary Meiyan Space |
| Latest Approvals | Hong Kong SAR market launch approvals for both PCL filler and FL skin booster (announced 21 Oct 2026) |
| Product 1 – PCL | Polycaprolactone Microsphere Facial Filler for Injection |
| Product 2 – FL | Hyaluronic Acid Sodium Composite Solution for Injection (skin booster) |
| Prior PCL Approval | NMPA (mainland China), April 2025 – correction of moderate‑to‑severe nasolabial fold wrinkles |
| Prior FL Approval | NMPA (mainland China) – twelve specifications, 0.5 mL/tube to 5 mL/tube; superficial dermis injection to temporarily improve skin dryness and dullness in adults |
| Development / Manufacturing | Self‑developed and self‑manufactured by Meiyan Space |
Product Profile – Polycaprolactone Microsphere Facial Filler (PCL)
- Dual‑Phase Action: Provides immediate filling to improve facial depressions, then transitions to a regenerative mode as the gel carrier is degraded and absorbed.
- Mechanism: The polycaprolactone (PCL) microspheres induce tissue regeneration, delivering a long‑lasting filling effect — the hallmark mechanism of collagen‑stimulating biostimulatory fillers.
- Approved Indication (Mainland): Correction of moderate‑to‑severe nasolabial fold wrinkles, per the April 2025 NMPA approval.
Product Profile – Hyaluronic Acid Sodium Composite Solution (FL) “Skin Booster”
- First‑in‑Category: China’s first composite solution skin booster containing L‑carnosine approved for direct facial use.
- Multi‑Mechanism Effects: Delivers hydration and moisturizing, antioxidant, anti‑glycation and anti‑inflammatory benefits in a single injectable formulation.
- Administration: Injection into the superficial dermis of the face to temporarily improve skin dryness and dullness in adults.
- Specification Range: Twelve NMPA‑approved specifications spanning 0.5 mL/tube to 5 mL/tube, offering flexible treatment protocols across facial indication areas.
Market Impact & Outlook
- Greater China Expansion: The twin Hong Kong approvals give Sihuan Pharmaceutical a second regulatory beachhead in the Greater China aesthetics market, following mainland NMPA clearances for both products.
- Portfolio Synergy: The pairing of a long‑lasting biostimulatory filler (PCL) with a multi‑action skin booster (FL) covers complementary segments — volumization and wrinkle correction on one side, skin quality and hydration on the other — enabling bundled clinic offerings.
- Aesthetics Tailwind: Minimally invasive facial procedures continue to be the growth engine of Greater China’s medical aesthetics market, with rising consumer demand for regenerative fillers and injectable skin‑quality treatments.
- Vertical Integration: Self‑development and self‑manufacturing through Meiyan Space preserves margin control and supply chain autonomy across the filler and skin booster portfolio.
- Disclosures: Commercial launch timing in Hong Kong, pricing, and revenue forecasts were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market adoption, and sales expectations for the PCL facial filler and FL skin booster in Hong Kong and other markets. Actual results may differ materially due to risks including distribution execution, clinic adoption, competitive dynamics, and regulatory developments. Market approval does not guarantee commercial success.-Fineline Info & Tech
